Anika Therapeutics Inc. (ANIK)
Anika Therapeutics Statistics
Share Statistics
Anika Therapeutics has 14.18M shares outstanding. The number of shares has increased by -4.59% in one year.
| Shares Outstanding | 14.18M |
| Shares Change (YoY) | -4.59% |
| Shares Change (QoQ) | -3.21% |
| Owned by Institutions (%) | 84.84% |
| Shares Floating | 14.13M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 390.36K, so 2.75% of the outstanding shares have been sold short.
| Short Interest | 390.36K |
| Short % of Shares Out | 2.75% |
| Short % of Float | 3.88% |
| Short Ratio (days to cover) | 5.08 |
Valuation Ratios
The PE ratio is -4.3 and the forward PE ratio is 25.04. Anika Therapeutics's PEG ratio is 0.13.
| PE Ratio | -4.3 |
| Forward PE | 25.04 |
| PS Ratio | 2.02 |
| Forward PS | 0.8 |
| PB Ratio | 1.57 |
| P/FCF Ratio | -103.95 |
| PEG Ratio | 0.13 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Anika Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.88 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -5.08 |
| Debt / FCF | -11.12 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $416.34K |
| Profits Per Employee | $-195.78K |
| Employee Count | 288 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | 6.06M |
| Effective Tax Rate | -219.39% |
Stock Price Statistics
The stock price has increased by -45.74% in the last 52 weeks. The beta is 0.81, so Anika Therapeutics's price volatility has been higher than the market average.
| Beta | 0.81 |
| 52-Week Price Change | -45.74% |
| 50-Day Moving Average | 16.04 |
| 200-Day Moving Average | 20.38 |
| Relative Strength Index (RSI) | 41.06 |
| Average Volume (20 Days) | 73.43K |
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 119.91M and earned -56.38M in profits. Earnings per share was -3.83.
| Revenue | 119.91M |
| Gross Profit | 76M |
| Operating Income | -5.1M |
| Net Income | -56.38M |
| EBITDA | -5.1M |
| EBIT | -5.1M |
| Earnings Per Share (EPS) | -3.83 |
Balance Sheet
The company has 55.63M in cash and 25.93M in debt, giving a net cash position of 29.7M.
| Cash & Cash Equivalents | 55.63M |
| Total Debt | 25.93M |
| Net Cash | 29.7M |
| Retained Earnings | 71.67M |
| Total Assets | 202.74M |
| Working Capital | 90.35M |
Cash Flow
In the last 12 months, operating cash flow was 5.4M and capital expenditures -7.73M, giving a free cash flow of -2.33M.
| Operating Cash Flow | 5.4M |
| Capital Expenditures | -7.73M |
| Free Cash Flow | -2.33M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 63.38%, with operating and profit margins of -4.25% and -47.02%.
| Gross Margin | 63.38% |
| Operating Margin | -4.25% |
| Pretax Margin | -2.31% |
| Profit Margin | -47.02% |
| EBITDA Margin | -4.25% |
| EBIT Margin | -4.25% |
| FCF Margin | -1.94% |
Dividends & Yields
ANIK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ANIK is $22, which is 56.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $22 |
| Price Target Difference | 56.9% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 3.93 |
| Piotroski F-Score | 2 |